Clinical Trial

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This phase I/II tests the safety, side effects, best dose and how well giving RYZ101 works for the treatment of patients with intracranial meningioma that is growing, spreading, or getting worse (progressive) or that has come back after a period of improvement (recurrent). RYZ101 is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving RYZ101 may be safe, tolerable and/or effective in treating patients with progressive or recurrent intracranial meningioma.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-08-27; most recent amendment 2026-05-20.
Status change: Suspended → Recruiting 2026-05-20
Status change: Recruiting → Suspended 2026-04-14
Status change: Not Yet Recruiting → Recruiting 2025-09-19
Trial Details
NCT Number NCT07150806
Lead Sponsor Joshua Palmer
Collaborators: RayzeBio, Inc.
Conditions Recurrent Meningioma
Enrollment 30 participants
Start Date 2025-11-12
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-13